Does ONVO stock pay a dividend?
A company's dividend expressed as a percentage of its current stock price. ONVO is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased. Percentage change in short interest from the previous report to the most recent report.
Is Organovo owned by insiders?
In the past three months, Organovo insiders have not sold or bought any company stock. Only 2.00% of the stock of Organovo is held by insiders. Only 26.29% of the stock of Organovo is held by institutions.
What is the PE (price targets) ratio of Organovo?
Only 26.29% of the stock of Organovo is held by institutions. The P/E ratio of Organovo is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is the new business strategy of Organovo?
In September 2020, Organovo began its new business strategy after the vote of the stockholders brought a new Board of Directors into control. Since that time, Organovo has rebuilt the R&D function of the
See more
How has Organovo's stock price performed in 2022?
Organovo's stock was trading at $3.63 on January 1st, 2022. Since then, ONVO shares have decreased by 42.4% and is now trading at $2.09. View the...
When is Organovo's next earnings date?
Organovo is scheduled to release its next quarterly earnings announcement on Tuesday, June 21st 2022. View our earnings forecast for Organovo .
How were Organovo's earnings last quarter?
Organovo Holdings, Inc. (NASDAQ:ONVO) released its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($1.00)...
When did Organovo's stock split? How did Organovo's stock split work?
Shares of Organovo reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. T...
Who are Organovo's key executives?
Organovo's management team includes the following people: Mr. Keith E. Murphy , Exec. Chairman & Principal Exec. Officer (Age 50, Pay $397.18k)...
What is Taylor Crouch's approval rating as Organovo's CEO?
3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com . Taylor Crouch has an approval rating of 38% among Organovo's employees. This...
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include Orchard Therapeutics (ORTX) , Brookline Capital Acquisition (BCAC) , SAB Biotherapeutics (SA...
What other stocks do shareholders of Organovo own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutic...
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
About Organovo
Organovo (NASDAQ:ONVO) Frequently Asked Questions
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
How much did Organovo stock fall in 2021?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Organovo stock. View analyst ratings for Organovo or view top-rated stocks.
Is Organovo Holdings a sell or buy signal?
The Organovo Holdings, Inc stock price fell by -0.47% on the last day (Tuesday, 6th Jul 2021) from $8.60 to $8.56. and has now fallen 4 days in a row. During the day the stock fluctuated 5.04% from a day low at $8.33 to a day high of $8.75. The price has been going up and down for this period, and there has been a 4.77% gain for the last 2 weeks. Volume has increased on the last day by 18 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 82 thousand shares were bought and sold for approximately $701.56 thousand.
What is Organovo Holdings Inc?
The Organovo Holdings, Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $8.99. On a fall, the stock will find some support from the long-term average at approximately $8.28. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, June 30, 2021, and so far it has fallen -8.94%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Organovo Holdings, Inc gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
Does market cap include convertible securities?
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The
